Company / Revenue per Share
CytomX Therapeutics, Inc. Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.55
FY2025
5-year range
$0.55 / $1.72
FY2021-FY2025
Trend
-68.0%
vs FY2024
Sector context
#116 of 154
Health Care
What the data says
CytomX Therapeutics, Inc.'s revenue per share of $0.55 is lower than 75% of companies in the Health Care sector (FY2025). Revenue per Share has fluctuated over the past 10 years, ranging from $0.41 in FY2016 to $2.20 in FY2020.
Based on SEC 10-K filings.
0.55 in FY2025 with a 5-year CAGR of -24.2%.
Declined from $1.50 to $0.55 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -11.7%
- 5-Year CAGR
- -24.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 154This company $0.55 Sector average $15.09
▼
-96.3% below sector average
Key checks
Key Insights
- In FY2025, revenue per share decreased 68.0% year-over-year.
- Ranks #116 out of 154 companies in the Health Care sector.
- Peak revenue per share was recorded in FY2020.
- Lowest revenue per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.55 | -68.0% |
| FY2024 | $1.72 | +14.7% |
| FY2023 | $1.50 | +87.3% |
| FY2022 | $0.80 | +40.7% |
| FY2021 | $0.57 | -74.1% |
| FY2020 | $2.20 | +74.6% |
| FY2019 | $1.26 | -4.3% |
| FY2018 | $1.32 | -29.1% |
| FY2017 | $1.86 | +351.5% |
| FY2016 | $0.41 | -53.7% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026